Objective-Although animal studies indicate that liver X receptor alpha (LXR␣) might influence risk of atherosclerosis, data in humans remain scarce. We tested the hypothesis that genetic variation in LXR␣ associates with risk of ischemic vascular disease and/or plasma lipid and lipoprotein levels in the general population. Methods and Results-We studied 10,281 white persons of Danish ancestry from a general population cohort, including 1,986 in whom ischemic heart disease (IHD) developed, and 989 in whom ischemic cerebrovascular disease developed. We examined another 51,429 white persons of Danish ancestry from a general population study, including 3,789 with IHD. We genotyped 10 genetic variants identified by resequencing LXR␣. Homozygosity for Ϫ840AA/ Ϫ115AA(ϭ2.7%) predicted hazard ratios of 1.3 (95% confidence interval, 1.0 -1.7) for IHD, 1.6 (1.2-2.2) for myocardial infarction, and 1.7 (1.3-2.4) for ischemic cerebrovascular disease. The corresponding odds ratios in the second cohort were 1.1 (0.9 -1.4) for IHD and 1.5 (1.1-2.0) for myocardial infarction. In the combined studies, odds ratios were 1.2 (1.0 -1.4) for IHD and 1.5 (1.2-1.9) for myocardial infarction. Homozygosity for Ϫ840AA/Ϫ115AA did not associate with lipid or lipoprotein levels. LXR␣ Ϫ1830TϾC (tagging the haplotype Ϫ1830C/Ϫ840A/Ϫ115A, all r 2 Ն0.97) associated with 91% increased transcriptional activity. Conclusion-This study suggests that functional genetic variation in LXR␣ predicts risk of ischemic vascular disease in the general population. (Arterioscler Thromb Vasc Biol. 2011;31:2990-2996.)
L iver X receptor alpha (LXR␣) is a nuclear receptor that plays a central role in both lipid metabolism and inflammation. 1 LXR␣ is activated by increased intracellular levels of oxysterols, a breakdown product of cholesterol, and orchestrates the removal of cholesterol from peripheral tissues by regulating genes involved in reverse cholesterol transport. 2 Other downstream effects of LXR␣ activation include increases in catabolism, biliary excretion, and conversion to fatty acids of cholesterol. 3 Furthermore, LXR␣ modulates the immune response via an antiinflammatory effect on macrophages. 4 Because plasma cholesterol levels as well as inflammatory processes are key players in the development of the atherosclerotic plaque, a possible role of LXR␣ in ischemic cardiovascular and ischemic cerebrovascular disease (ICVD) has been the focus of intense research. 1 Several studies have demonstrated that LXR␣ agonists attenuate the development of atherosclerosis in mice and protect against neuronal damage in animal models of ischemic stroke (IS). 5, 6 Further underpinning a possible role of LXR␣ in ischemic vascular disease is the observation that LXR␣ knockout mice display an increased susceptibility to atherosclerosis and IS. 6, 7 However, data pertaining to LXR␣ biology in humans remain scarce.
We hypothesized that genetic variation in LXR␣ might influence risk of ischemic vascular disease and/or plasma lipid and lipoprotein levels in the general population. To test this hypothesis, we resequenced the LXR␣ gene in 190 individuals and genotyped the identified genetic variants in the Copenhagen City Heart Study (CCHS), a study of 10,281 white individuals of Danish ancestry from the general population followed for up to 33 years. We subsequently examined risk of ischemic heart disease (IHD), myocardial infarction (MI), ICVD, and IS, plasma lipid and lipoprotein levels, and biochemical markers of inflammation as a function of LXR␣ genotype. Any genetic association identified with risk of ischemic vascular disease was validated in the Copenhagen General Population Study (CGPS), a study comprising 51,429 white individuals of Danish ancestry from the general population.
Methods
Studies were approved by institutional review boards and Danish ethical committees and conducted according to the Declaration of Helsinki. Written informed consent was obtained from all participants. All participants were white and of Danish descent: The national Danish Central Person Register registers date and place of birth and death, gender and descent, and all immigration/emigration to/from Denmark of all inhabitants in Denmark. Danish descent is defined as an individual born in Denmark with Danish citizenship with both parents also born in Denmark with Danish citizenship. Because there was virtually no immigration before the 1990s with the exception from nearby Scandinavian countries, this is an ethnically extremely homogeneous population. Furthermore, at the time of examination, the examiner registered the ethnicity of the participants in both studies.
Study Cohorts

The CCHS
The CCHS 8 -10 is a study of the Danish general population initiated from 1976 to 1978 with follow-up examinations in 1981 to 1984, 1991 to 1994, and 2001 to 2003 . Individuals were randomly selected to represent the Danish general population aged 20 to 80ϩ years. We included 10,281 participants who gave blood for DNA analysis at the 1991 to 1994 and/or 2001 to 2003 examinations in the present analysis. Of these, 1986 developed IHD, 950 suffered an MI, 989 developed ICVD, and 764 had IS during follow-up. All endpoints and data collection were recorded in the follow-up period from January 1976 through May 2009. Follow-up was up to 33 years and was 100% complete;ie, no participants were lost to follow-up.
The CGPS
The CGPS 8,11 is a mainly cross-sectional study of the Danish general population initiated in 2003 and is still recruiting. However, as endpoints were collected until May 2009, this study is also partly prospective. The aim is to recruit a total of 100,000 participants ascertained exactly as in the CCHS but with a focus on all multifactorial diseases including IHD. At the time of genotyping for the present study, 51,429 participants had been included. Of these, 3789 had IHD and 1554 had suffered an MI. Information on diagnoses of IHD and MI was ascertained as in the CCHS. However, ICVD and IS diagnoses were not validated in the CGPS, and these endpoints were therefore not included. For a detailed description of the diagnostic criteria, please see the Supplemental Methods, available online at http://atvb.ahajournals.org.
Laboratory Analyses
Plasma levels of total cholesterol, LDL cholesterol, apolipoprotein B, HDL cholesterol, apolipoprotein A1, triglycerides, and fibrinogen were measured using standard hospital assays (Konelab, Helsinki, Finland, and Boehringer Mannheim, Mannheim, Germany). LDL cholesterol was calculated using the Friedewald equation if the triglyceride level was less than 4 mmol per liter (354 mg per deciliter) and was measured directly for higher triglyceride levels. High-sensitivity C-reactive protein was measured by nephelometry (Dako, Glostrup, Denmark).
Other Covariates
Body mass index was weight in kilograms (kg) divided by height in meters squared (m 2 ). Hypertension, diabetes mellitus, smoking status, and use of lipid-lowering drugs were dichotomized and defined as hypertension (systolic blood pressure Ͼ140 mm Hg or diastolic blood pressure Ͼ90 mm Hg or use of antihypertensive medication) versus no hypertension, diabetes (self-reported disease, use of insulin, use of oral hypoglycemic drugs, and/or nonfasting plasma glucose Ͼ11.0 mmol/L) versus no diabetes, current smokers versus nonsmokers, and use of lipid-lowering drugs (yes/no).
Gene Sequencing
We sequenced LXR␣ in individuals from the CCHS with the lowest 1% (nϭ95) and highest 1% (nϭ95) levels of plasma HDL cholesterol for age (in 10-year age groups) and sex. 8, 12 Ten PCR fragments covering 1,000 basepairs of the region upstream of the ATG translation start site (first Aϭnucleotide 36 in exon 2, position 47280768 on chromosome 11, NCBI genome build 37.1), and all 9 protein-coding exons and exon-intron boundaries were amplified and sequenced on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems Inc.).
Genotyping
An ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) was used for genotyping by TaqMan-based assays. All promoter and nonsynonymous variants 
LXR␣ ؊1830T>C Expression Analysis
The region of the human LXR␣ promoter between nucleotides Ϫ2009 and Ϫ1168 (relative to the ATG start codon) was amplified by PCR using human genomic DNA as a template and the following primers: Forward (Ϫ2009): 5Ј CGGGGTACCCTATAGTCTCAG-TAGCTG 3Ј; Reverse (Ϫ1168): 5Ј CCAAGCTTTGTCCA-GAAGTCTCGGT 3Ј and was cloned at the Kpn I/Hind III sites of the plasmid pGL4.10 (Promega). The LXR␣ (Ϫ1830TϾC)-Luc plasmid was generated by overlap extension PCR using the following internal mutagenesis primers: Forward: 5Ј GCAGATTTCCTAC-CAAAGGCTCTCC 3Ј; Reverse: 5Ј GGAGAGCCTTTGGTAG-GAAATCTGC 3Ј along with the external primers described above. The amplified PCR fragment was cloned at the Kpn I/HinD III site of the pGL4.10 vector. All plasmids were verified by sequencing. Transient transfections of HepG2 cells with the LXR␣-Luc reporter vectors, along with an expression vector for beta galactosidase (CMV-␤-gal), were performed using the calcium phosphate precipitation method. Normalization for transfection efficiency was performed by ␤-galactosidase assays, and results were expressed as the normalized relative percent promoter activity from 5 independent transfections. Luciferase assays were performed using the luciferase assay kit from Promega Corp. according to the manufacturer's instructions.
Statistical Analysis
Stata software, version 10 (Stata Corp, College Station, TX) was used for all analyses. Two-sided probability values less than 0.05 were considered significant. The Mann-Whitney U test or Kruskal-Wallis analysis of variance was used for continuous variables, and Pearson 2 test was used for categorical values. Trend tests were by Cuzick nonparametric test for trend. Risk of IHD, MI, ICVD, or IS as a function of LXR␣ genotype was examined prospectively in the CCHS using left truncation (or delayed entry). Cox regression models with age as the time scale, adjusted for age, sex, body mass index, hypertension, diabetes, smoking, use of lipid lowering drugs, plasma levels of total cholesterol, HDL cholesterol, and triglycerides were used to estimate hazard ratios. Proportionality of hazards over time was assessed by plotting Ϫln[Ϫln(survival)] versus ln(analysis time). There was no suspicion of nonparallel lines. Competing risk of any death was accounted for by censoring at the date of death. In the CGPS, odds ratios for IHD and MI (adjusted for all covariates listed above) were calculated by conditional logistic regression analysis. Interaction of genotype with all covariates listed above was evaluated by including 2-factor interaction terms between genotype and covariates, one at a time, in the Cox regression model.
Results
Baseline characteristics of participants in the CCHS and the CGPS by disease status are presented in Table 1 .
Resequencing and Genotyping
LXR␣ is known to regulate several genes involved in reverse cholesterol transport, and genetic variation in this gene might therefore affect HDL cholesterol levels. Therefore, to increase the likelihood of identifying genetic variants with effect on HDL cholesterol levels, we resequenced 1000 basepairs upstream of the ATG start site and all 9 protein-coding exons in individuals with the lowest 1% (nϭ95; 190 alleles) and highest 1% (nϭ95; 190 alleles) HDL cholesterol levels in the CCHS. 8, 12 Of the 13 variants identified using this approach, 7 had minor allele frequencies Ͻ1%, and of these 4 were new (Ϫ524GϾA, Ϫ288AϾG, Ϫ44CϾA, 385GϾA/G129R; Table 2 ).
We genotyped the 9 variants located upstream from the ATG translation start site and G129R, the rare nonsynonymous variant, in the entire CCHS (nϭ10,281). The genotyped variants tag 43% (3/7) of common variants across the LXR␣ region according to HapMap. The genotyping succes rate was Ͼ99.9%. All variants were in Hardy-Weinberg equilibrium (probability values from 0.71-0.99). Three common variants, Ϫ1830TϾC (rs3758674), Ϫ840CϾA (rs61896015), and Ϫ115GϾA (rs12221497) were in strong pairwise linkage disequilibrium (all pairwise r 2 Ն0.97, Supplemental Figure I) . The minor allele frequency (16%) and the genotype distribution of Ϫ115GϾA in both our studies (Table 3) were very similar to frequencies in a Swedish population, 14 and to frequencies in other European populations. 13, 15, 16 Furthermore, 4 common ancestry informative 17 SNPs in, respectively, APOE (22/32/42/33/43/44; rs429358 and rs7412), CETP (Taq1b, rs708272), and APOB (XbaI, rs693) were equally distributed between the 3 LXR␣ Ϫ115GϾA genotypes in our studies (Supplemental Table I ).
Risk of Ischemic Vascular Disease
The cumulative incidences of IHD, MI, ICVD, and IS were increased in Ϫ840AA/Ϫ115AA homozygotes versus Ϫ840CC/Ϫ115GG homozygotes in the CCHS (Log-rank probability values from 0.02 to Ͻ0.001; Figure 1 ). Homozygosity for Ϫ840AA/Ϫ115AA predicted risk of IHD (hazard ratio [HR] 1.3; 95% confidence interval [CI]: 1.0 -1.7; Pϭ0.02), MI (HR 1.6; 95 CI: 1.2-2.2; Pϭ0.005), ICVD (HR 1.7; 95% CI: 1.3-2.4; Pϭ0.001), and IS (HR 1.9; 95% CI: 1.4 -2.7; PϽ0.001) versus Ϫ840CC/Ϫ115GG homozygotes (Figure 2, left column) . The corresponding HRs using a recessive model (Ϫ840AA/Ϫ115AA versus Ϫ840CC/ Ϫ115GG and Ϫ840CA/Ϫ115GA combined) were 1.4 (95% CI: 1.1-1.7) for IHD, 1.6 (95% CI: 1.1-2.2) for MI, 1.7 (95% CI: 1.3-2.4) for ICVD, and 1.9 (95% CI: 1.4 -2.7) for IS. Of the 989 participants in the CCHS who developed ICVD, 367 (37%) also developed IHD during follow-up. In order to test whether the observed association of Ϫ840AA/Ϫ115AA with ICVD and IS in the CCHS could be explained by an overlap of diagnoses, we excluded all participants with IHD (nϭ1,986). In this setting, Ϫ840AA/Ϫ115AA still predicted risk of ICVD (HR 1.5; 95% CI: 1.0 -2.4; Pϭ0.05) and IS (HR 1.9; 95% CI: 1.2-3.0; Pϭ0.01). None of the remaining variants associated consistently with disease endpoints (Supplemental Figure II) .
In the CGPS, homozygosity for Ϫ840AA/Ϫ115AA versus Ϫ840CC/Ϫ115GG associated with odds ratios (ORs) for IHD and MI, of 1.1 (95% CI: 0.9 -1.4; Pϭ0.29) and 1.5 (95% CI: 1.1-2.0; Pϭ0.008; Figure 2 , middle column). The corresponding ORs using a recessive model were 1.1 (95% CI: 0.9 -1.4) for IHD, and 1.5 (95% CI: 1.1-2.0) for MI. In the combined studies, homozygosity for Ϫ840AA/Ϫ115AA versus Ϫ840CC/Ϫ115GG associated with risk of IHD (OR 1.2; 95% CI: 1.0 -1.4; Pϭ0.02) and MI (OR 1.5; 95% CI: 1.2-1.9; PϽ0.001; Figure 2 , right column).
There were no interactions between Ϫ840CϾA/ Ϫ115GϾA genotype and covariates from Table 1 cholesterol, HDL cholesterol, triglycerides, high-sensitivity C-reactive protein, and fibrinogen on risk of ischemic cardiovascular disease.
or total
Lipids, Lipoproteins, and Inflammatory Markers
LXR␣ Ϫ840CϾA/Ϫ115GϾA genotype did not associate with plasma levels of total cholesterol, LDL cholesterol, apolipoprotein B, HDL cholesterol, apolipoprotein A1, triglycerides, high-sensitivity C-reactive protein, or fibrinogen in the CCHS or in the CGPS ( Table 3 ). None of the remaining 9 variants genotyped in the CCHS were associated with lipid or lipoprotein levels (Supplemental Figure III) , or with inflammatory markers (data not shown).
LXR␣ ؊1830T>C Promoter Function
The relative luciferase activity driven by the LXR␣ promoter with the mutant C at position Ϫ1830 relative to the ATG start site was increased by 91% compared with the wild-type promoter with T at position Ϫ1830 (Pϭ0.005; Figure 3 , mean of 5 experiments).
Discussion
The principal finding of this study is that homozygosity for an in vitro functional genetic variant in the promoter region of LXR␣ predicted increased risk of ischemic vascular disease without affecting plasma lipid or lipoprotein levels.
Our study is the first to examine the association of genetic variation in LXR␣ with risk of ischemic vascular disease in the general population. Other studies have reported associations with obesity, 14 life span, 18 and plasma lipid levels 13, 15, 19, 20 for common genetic variants in LXR␣. LXR␣ and LXR␤ have similar functions in lipid metabolism and inflammation, but whereas LXR␣ is expressed in the liver, adipose tissue, kidney, adrenals, and macrophages, LXR␤ is expressed ubiquitously. 1 Genetic variation in LXR␤ has been associated mainly with obesity 14 and type 2 diabetes, [21] [22] [23] both well-known risk factors for ischemic vascular disease.
Constructs based on the region harboring Ϫ840CϾA and Ϫ115GϾA (immediately upstream of the ATG start site) did not show any luciferase activity, likely reflecting a lack of promoter function for this region. A functional promoter region of LXR␣ has previously been identified approximately Ϫ3000 to Ϫ1300 basepairs upstream from the ATG start codon. 24 This region harbors the SNP Ϫ1830TϾC shown to be in strong linkage disequilibrium with Ϫ840CϾA and Ϫ115GϾA. 13 We genotyped Ϫ1830TϾC in 683 individuals from the CCHS and found a similar high degree of linkage between this variant and Ϫ840CϾA and Ϫ115GϾA in our study (all pairwise r 2 Ն0.97), and hypothesized that Ϫ1830TϾC could be the functional variant underlying the increased risk observed in Ϫ840AA/Ϫ115AA homozygotes. Indeed, luciferase assays showed a strong increase in LXR␣ promoter activity associated with the rare C-allele of Ϫ1830TϾC. The implication of these data is that an in vitro functional promoter variant in LXR␣ associates with elevated risk of ischemic vascular disease.
Animal studies suggest that LXR␣ activation exerts an atheroprotective effect. [5] [6] [7] Intriguingly, genetic variation that increased LXR␣ transcription in vitro associated with increased risk of ischemic vascular disease in our study in humans. Mechanistically, this might be explained by the increase in production of atherogenic triglyceride-rich very low density lipoproteins associated with LXR␣ activation in mice. 25 In support of this, Robitaille et al 13 (nϭ784, mean age 49 years) found that Ϫ840CϾA/Ϫ115GϾA associated with slightly elevated plasma levels of total cholesterol and triglycerides in heterozygotes and homozygotes combined versus noncarriers. Legry et al 20 recently reported that LXR␣ Ϫ115GϾA associated with 10% lower HDL cholesterol levels (a marker of increased triglyceride levels in epidemiological studies) in a study of European adolescents (nϭ1144, mean age 15 years). In contrast, we genotyped Ϫ115GϾA (tagging the haplotype Ϫ1830C/Ϫ840A/Ϫ115A) in more than 60,000 individuals (mean age 56 years) and did not detect any association with plasma lipid or lipoprotein levels. Possible explanations for this include differences in study designs, in characteristics of participants (fasting versus nonfasting triglyceride, body mass index, diabetes, and age), or possible interactions with environmental factors, especially diet. 13, 20 However, it is worth noting that genetic variants with effect on risk of ischemic cardiovascular disease without influencing plasma lipid and lipoprotein levels are not unknown. 26 -28 Because a 2-fold difference in transcription levels does not appear to affect plasma lipid levels in the present study, these results seem to suggest that, at least in man, non-lipid-related effects of LXR␣ are more important than lipid-related effects in modulating risk of ischemic vascular disease.
The association between Ϫ840CϾA/Ϫ115GϾA and ischemic cardiovascular disease exhibits recessive inheritance. One might perhaps have expected additive inheritance from a promoter variant. However, we have previously shown that an in vitro functional promoter variant in ZNF202 (a regulatory gene implicated in lipid metabolism, not unlike LXR␣), associates with risk of IHD in a recessive manner. 27 LXR␣ has not been implicated in genomewide association studies of ischemic cardiovascular disease 29 or stroke. 30 The variants showing association with ischemic endpoints in our study are well covered both in HapMap (Ϫ115GϾA) and on commercially available genotyping chips. However, the recessive nature of the association, the low frequency of the homozygote at-risk genotype (2.7%), and the relatively moderate risk estimates (Յ1.9 for all endpoints) observed in the present study together make it unlikely that this association will be picked up in the discovery phase of most genomewide association studies, because of lack of power and/or the stringent probability values in these studies. 31, 32 Of potential clinical relevance, homozygosity for Ϫ840AA/Ϫ115AA might eventually be used as part of a genetic risk prediction algorithm. 32 We suggest that additional validation of the association should be carried out by other groups before including the variant in such algorithms.
Associations between a rare homozygote genotype and risk are extremely susceptible to population stratification. However, (1) all participants were white and of Danish descent;
(2) minor allele and genotype frequencies of the Ϫ115GϾA genotype were similar to frequencies in other Scandinavian and European countries; (3) all SNPs studied were in Hardy-Weinberg equilibrium in both our studies (deviation from Hardy-Weinberg equilibrium may indicate population stratification 33 ); and (4) the genotype distribution of ancestry informative SNPs in APOE, CETP, and APOB did not differ by Ϫ115GϾA genotype, suggesting that Ϫ115AA homozygotes were of the same ancestry as other members of the cohort. In summary, population stratification is highly unlikely in our studies.
In conclusion, this study suggests that functional genetic variation in LXR␣ predicts risk of ischemic vascular disease in the general population. Although additional replication in yet other cohorts is warranted, the data presented here bridge the gap between animal and human studies, and add to the growing body of evidence in favor of LXR␣ as an important player in ischemic vascular disease. 
